Last update 13 Dec 2025

18F-GE226

Overview

Basic Info

Drug Type
Affibody, Diagnostic radiopharmaceuticals
Synonyms
luorine18 GE 226, 18FFBAZHER22891, GE 226
+ [1]
Target
HER2
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Locally advanced breast cancer
Inactive Indication
Metastatic breast cancer
Originator Organization
Affibody ABAffibody ABGE Healthcare Ltd. (United Kingdom)
Active Organization
Imperial College LondonImperial College London
Inactive Organization
GE Healthcare Ltd. (United Kingdom)Affibody Medical AB
License Organization
Affibody ABAffibody ABGE Healthcare, Inc.
Drug Highest PhaseClinical
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with 18F-GE226
NCT03827317
/ RecruitingNot ApplicableIIT
HERPET: A Mechanistic Non-Invasive Imaging Study of HER2 Expression in Breast Cancer Using [18F]GE-226 Positron Emission Tomography
100 Clinical Results associated with 18F-GE226
Login to view more data
100 Translational Medicine associated with 18F-GE226
Login to view more data
100 Patents (Medical) associated with 18F-GE226
Login to view more data
100 Deals associated with 18F-GE226
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic breast cancerPhase 1
United Kingdom
Affibody Medical AB
08 Mar 2019
Locally advanced breast cancerClinical
United Kingdom
Imperial College LondonImperial College London
08 Mar 2019
Breast CancerPreclinical
United Kingdom
GE Healthcare Ltd. (United Kingdom)
15 Apr 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03827317 (HERPET, ASCO2022)
ManualManual
Not Applicable
Breast Cancer
HER2 Positive
20
(HER2 positive)
tfldjbmzyv(hlpzrcmcya): P-Value = <0.001
View more
Positive
02 Jun 2022
(HER2 negative)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free